- Diagnostic Différentiel
Drug Information for Idamycin idarubicin hydrochloride for injection, USP (Pharmacia and Upjohn Co.): OVERDOSAGE
- CLINICAL STUDIES
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Diseases/Conditions Related to Idamycin idarubicin hydrochloride for injection, USP (Pharmacia and Upjohn Co.)
- Liens externes liés à Idamycin idarubicin hydrochloride for injection, USP (Pharmacia and Upjohn Co.)
There is no known antidote to IDAMYCIN (idarubicin hydrochloride for injection, USP). Two cases of fatal overdosage in patients receiving therapy for AML have been reported. The doses were 135 mg/m2 over 3 days and 45 mg/m2 of idarubicin and 90 mg/m2 of daunorubicin over a three day period.
It is anticipated that overdosage with idarubicin will result in severe and prolonged myelosuppression and possibly in increased severity of gastrointestinal toxicity. Adequate supportive care including platelet transfusions, antibiotics and symptomatic treatment of mucositis is required. The effect of acute overdose on cardiac function is not fully known, but severe arrhythmia occurred in 1 of the 2 patients exposed. It is anticipated that very high doses of idarubicin may cause acute cardiac toxicity and may be associated with a higher incidence of delayed cardiac failure.
Disposition studies with idarubicin in patients undergoing dialysis have not been carried out. The profound multicompartment behavior, extensive extravascular distribution and tissue binding, coupled with the low unbound fraction available in the plasma pool make it unlikely that therapeutic efficacy or toxicity would be altered by conventional peritoneal or hemodialysis.
- Drug Information Provided by National Library of Medicine (NLM).